Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 May;111(5):1129-36.
doi: 10.1097/AOG.0b013e3181705d0e.

CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial

Eric D Levens  1 , Clariss Potlog-Nahari, Alicia Y Armstrong, Robert Wesley, Ahalya Premkumar, Diana L Blithe, Wendy Blocker, Lynnette K Nieman
Affiliations
Randomized Controlled Trial

CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial

Eric D Levens et al. Obstet Gynecol. 2008 May.

Abstract

Objective: To evaluate whether 3-month administration of CDB-2914, a selective progesterone receptor modulator, reduces leiomyoma size and symptoms.

Methods: Premenopausal women with symptomatic uterine leiomyomata were randomly assigned to CDB-2914 at 10 mg (T1) or 20 mg (T2) daily or to placebo (PLC) for 3 cycles or 90-102 days if no menses occurred. The primary outcome was leiomyoma volume change determined by magnetic resonance imaging at study entry and within 2 weeks of hysterectomy. Secondary outcomes included the proportion of amenorrhea, change in hemoglobin and hematocrit, ovulation inhibition, and quality-of-life assessment.

Results: Twenty-two patients were allocated, and 18 completed the trial. Age and body mass index were similar among groups. Leiomyoma volume was significantly reduced with CDB-2914 administration (PLC 6%; CDB-2914 -29%; P=.01), decreasing 36% and 21% in the T1 and T2 groups, respectively. During treatment, hemoglobin was unchanged, and the median estradiol was greater than 50 pg/mL in all groups. CDB-2914 eliminated menstrual bleeding and inhibited ovulation (% ovulatory cycles: CDB-2914, 20%; PLC, 83%; P=.001). CDB-2914 improved the concern scores of the uterine leiomyoma symptom quality-of-life subscale (P=.04). One CDB-2914 woman developed endometrial cystic hyperplasia without evidence of atypia. No serious adverse events were reported.

Conclusion: Compared with PLC, CDB-2914 significantly reduced leiomyoma volume after three cycles, or 90-102 days. CDB-2914 treatment resulted in improvements in the concern subscale of the Uterine Fibroid Symptom Quality of Life assessment. In this small study, CDB-2914 was well-tolerated without serious adverse events. Thus, there may be a role for CDB-2914 in the treatment of leiomyomata.

Clinical trial registration: ClinicalTrials.gov,www.clinicaltrials.gov, NCT00290251

Level of evidence: I.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient enrollment, randomization, and outcomes. Levens. CDB-2914 for Uterine Leiomyomata. Obstet Gynecol 2008.
See this image and copyright information in PMC

Comment in

References

    1. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol. 1990;94:435–438. - PubMed
    1. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990–1997. Obstet Gynecol. 2002;99:229–234. - PubMed
    1. Jacobson GF, Shaber RE, Armstrong MA, Hung YY. Changes in rates of hysterectomy and uterine conserving procedures for treatment of uterine leiomyoma. Am J Obstet Gynecol. 2007;196:601, e1–e5. - PubMed
    1. Chegini N, Ma C, Tang XM, Williams RS. Effects of GnRH analogues, ’add-back’ steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod. 2002;8:1071–1078. - PubMed
    1. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003;111:1037–1054. - PMC - PubMed

Publication types

Associated data